Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of Intravenous Varespladib, a Phospholipase A2 Inhibitor, for the Treatment of Snakebite Envenoming

Award Number: R01FD007839
ORGANIZATION: FOOD AND DRUG ADMINISTRATION
OPDIV: FDA
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2023
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

Development of Intravenous Varespladib, a Phospholipase A2 Inhibitor, for the Treatment of Snakebite Envenoming - 1 Project Summary 2 3 In experimental studies, direct inhibition of the snake venom toxin secretory phospholipase A2 (sPLA2) results 4 in significant improvements in sPLA2-mediated toxicities, but the benefits of sPLA2 inhibition in humans bitten 5 by snakes remains unknown. Ophirex is a Public Benefit Corporation whose mission is to reduce death and 6 disability from snakebite envenoming (SBE) through the development of varespladib, a highly potent inhibitor of 7 snake venom sPLA2. Snake venom sPLA2 and sPLA2-like proteins are found in 95% of medically important 8 venomous snakes worldwide and thought to be found in all venomous snakes native to the United States. These 9 proteins are key contributors to neuromuscular paralysis, coagulopathy, cardiotoxicity, renal toxicity, and skeletal 10 muscle injury. Antibody therapies (“antivenoms”) have limited efficacy against sPLA2 because of the generally 11 low antigenicity of sPLA2 and because of physiologic barriers to the entry of antibodies into important 12 compartments (e.g., muscle, neuromotor junctions). Varespladib has been found to rescue mice and pigs from 13 lethal envenoming from a variety of species of snake, even when given at a point in time when antivenom is no 14 longer able to rescue the animals. Varespladib also acts synergistically with antivenom: In preclinical studies, 15 the combination of varespladib and antivenom results in greater inhibition of sPLA2 and greater protective 16 benefits from a range of sPLA2-mediated toxicities than would be expected from summing the benefits of the 17 two therapies on their own. The overarching goal of this project is to conduct research to support regulatory 18 approval of an intravenous formulation of varespladib for SBE. This will be achieved through the completion of 19 a Phase IIb double-blind randomized controlled trial of varespladib in 110 patients bitten by venomous snakes 20 and receiving care at sites in the U.S. and India. All patients will receive standard of care treatment, including 21 antivenom. Patients will receive a continuous infusion of varespladib or normal saline for at least 6 hours. After 22 6 hours of whenever they are clinically stable and able to tolerate oral medication, patients will be switched to 23 oral treatment with varespladib-methyl or placebo. The total duration of treatment will be 7 days. The primary 24 outcome will be the change from baseline to the average at 3 and 6 hours of the Snakebite Severity Score, which 25 assesses key snake venom toxicities of the hematologic, neurologic, renal, cardiovascular, and pulmonary 26 systems. The proposed work will also utilize two innovative approaches to expanding the findings from the trial 27 to other important populations: (1) Physiologically-based pharmacokinetic modeling will be used to identify an 28 appropriate dosing strategy in pediatric patients and to enhance available pediatric safety and efficacy data; and 29 (2) A simulation model will be used to estimate the clinical effect of varespladib in patients bitten by snake species 30 not well-represented in the trial. The results of the proposed work will be used to support regulatory approval 31 with the potential to transform the paradigm for snakebite treatment and to save thousands of lives each year.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,109,888 )
2025	2025	OPHIREX, INC	5643 PARADISE DR STE 2	CORTE MADERA	CA	94925	MARIN	USA	Food and Drug Administration Research	003	3	9/26/2025	NON-COMPETING CONTINUATION	$103,699
2025	2025	OPHIREX, INC	5643 PARADISE DR STE 2	CORTE MADERA	CA	94925	MARIN	USA	Food and Drug Administration Research	001	3	9/22/2025	NON-COMPETING CONTINUATION	$221,577
2025	2025	OPHIREX, INC	5643 PARADISE DR STE 2	CORTE MADERA	CA	94925	MARIN	USA	Food and Drug Administration Research	002	3	9/25/2025	NON-COMPETING CONTINUATION	-$103,699
2025	2025	OPHIREX, INC	5643 PARADISE DR STE 2	CORTE MADERA	CA	94925	MARIN	USA	Food and Drug Administration Research	000	3	7/21/2025	NON-COMPETING CONTINUATION	$888,311
														Subtotal = $1,109,888

Issue Date FY: 2024 ( Subtotal = $886,309 )
2024	2024	OPHIREX, INC	5643 PARADISE DR STE 2	CORTE MADERA	CA	94925	MARIN	USA	Food and Drug Administration Research	001	2	9/15/2024	NON-COMPETING CONTINUATION	$886,309
2024	2024	OPHIREX, INC	5643 PARADISE DR STE 2	CORTE MADERA	CA	94925	MARIN	USA	Food and Drug Administration Research	002	2	9/20/2024	NON-COMPETING CONTINUATION	$0
2024	2023	OPHIREX, INC	5643 PARADISE DR STE 2	CORTE MADERA	CA	94925	MARIN	USA	Food and Drug Administration Research	000	1	4/30/2024	NEW	$0
														Subtotal = $886,309

Issue Date FY: 2023 ( Subtotal = $894,459 )
2023	2023	OPHIREX, INC.	5643 PARADISE DR #2	CORTE MADERA	CA	94925	MARIN	USA	Food and Drug Administration Research	001	1	9/20/2023	NEW	$0
2023	2023	OPHIREX, INC.	5643 PARADISE DR #2	CORTE MADERA	CA	94925	MARIN	USA	Food and Drug Administration Research	000	1	9/20/2023	NEW	$894,459
														Subtotal = $894,459

Grand Total All Awards = $2,890,656

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of Intravenous Varespladib, a Phospholipase A2 Inhibitor, for the Treatment of Snakebite Envenoming

Award Number: R01FD007839

ORGANIZATION: FOOD AND DRUG ADMINISTRATION

OPDIV: FDA

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2023

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer